Blood Transfusion for Thalassemia: Indications, Protocols, and Complications

Thalassemia syndromes (α/β) cause ineffective erythropoiesis and hemolytic anemia. Transfusion is life-sustaining for transfusion-dependent thalassemia (TDT).

Transfusion Goals

  • Maintain pre-transfusion Hb 9–10.5 g/dL (TDT); higher if cardiac disease.
  • Suppress endogenous erythropoiesis (prevents extramedullary hematopoiesis, bone deformities).
  • Interval: every 2–4 weeks (adjusted to Hb drift).

Blood Product Specifications

  • Leukoreduced (pre-storage) → reduces alloimmunization, CMV, febrile reactions.
  • Phenotype-matched (Rh, Kell, Duffy, Kidd) → delays alloimmunization.
  • Irradiated (25 Gy) → prevents TA-GVHD (if HLA risk).
  • Washed if severe allergic reactions.

Complications

  • Iron overload: Inevitable (1 unit = 200–250 mg Fe). Requires chelation (deferasirox, deferiprone, deferoxamine). Monitor ferritin, MRI T2* (heart/liver).
  • Alloimmunization: 10–30% despite matching; complicates future transfusion.
  • Infections: Residual risk (HBV, HCV, HIV <1/1M; bacterial sepsis rare).
  • Transfusion reactions: Febrile non-hemolytic, allergic, TRALI, TACO, DHTR.

Curative Option

Allogeneic HSCT (matched sibling best) or gene therapy (betibeglogene autotemcel for β-thalassemia).

Comprehensive care (hematology, cardiology, endocrinology, psychology) enables near-normal lifespan.

Blood Disorders - Related Articles